Search Results - "Early, Amy"

Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction by Early, Amy P., Moon, Wong

“…The medical literature defining breast cancer recurrence and secondary cancers after autologous tissue reconstruction for breast cancer is sparse. We sought to…”
Get full text

Barriers to and facilitators of community participation among Latinx migrants with disabilities in the United States and Latinx migrant workers in Canada: An ecological analysis by Suarez‐Balcazar, Yolanda, Viquez, Floryana, Miranda, Daniela, Early, Amy R.

“…Individuals migrate to improve their wellbeing and quality of life, and often experience adverse situations, both during the process of migration and once…”
Get full text

SSO-ASTRO consensus guidelines for breast-conserving surgery with whole-breast radiation: in regard to Moran et al by Early, Amy P

Get full text

Walkability Safety and Walkability Participation: A Health Concern by Suarez-Balcazar, Yolanda, Early, Amy R., Garcia, Claudia, Balcazar, Daniel, Arias, Dalmina L., Morales, Miguel

“…Walking is correlated with both improved physical and emotional health. However, walking behavior is often heavily influenced by environmental conditions. The…”
Get full text

In Regard to Moran et al by Early, Amy P., MD, FACP

Get full text

Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment by Dhakal, Ajay, Matthews, Christina M., Levine, Ellis Glenn, Salerno, Kilian Elizabeth, Zhang, Fan, Takabe, Kazuaki, Early, Amy P., Edge, Stephen B., O'Connor, Tracy, Khoury, Thaer, Young, Jessica S., Opyrchal, Mateusz

“…This retrospective study examined outcomes of hormone receptor-positive (HR+) human epidermal growth factor receptor 2 nonamplified (HER2−) metastatic breast…”
Get full text

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience by Alaklabi, Sabah, Roy, Arya Mariam, Attwood, Kristopher, George, Anthony, O'Connor, Tracey, Early, Amy, Levine, Ellis G, Gandhi, Shipra

“…It is critically important to study the real-world data of FDA-approved medications to understand the response rates and toxicities observed in the real-world…”
Get full text

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx by Gandhi, Shipra, Opyrchal, Mateusz, Grimm, Melissa J, Slomba, Ronald T, Kokolus, Kathleen M, Witkiewicz, Agnieszka, Attwood, Kristopher, Groman, Adrienne, Williams, Lauren, Tarquini, Mary Lynne, Wallace, Paul K, Soh, Kah Teong, Minderman, Hans, Maguire, Orla, O’Connor, Tracey L, Early, Amy P, Levine, Ellis G, Kalinski, Pawel

“…BackgroundPresence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts the effectiveness of cancer immunotherapies. The ability of…”
Get full text

Current overview of the management of urogenital atrophy in women with breast cancer by Pruthi, Sandhya, Simon, James A, Early, Amy P

“…Systemic treatments for women with breast cancer frequently induce urogenital symptoms that can negatively impact a women's quality of life. Urogenital atrophy…”
Get more information

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib by Dhakal, Ajay, Antony Thomas, Roby, Levine, Ellis G, Brufsky, Adam, Takabe, Kazuaki, Hanna, Matthew G, Attwood, Kristopher, Miller, Austin, Khoury, Thaer, Early, Amy P, Soniwala, Saif, O’Connor, Tracy, Opyrchal, Mateusz

“…Background: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified…”
Get full text

Neuroendocrine Carcinoma of the Breast With Endobronchial Metastases and Syndrome of Inappropriate Antidiuretic Hormone Secretion by Maqsood, Anaum, Khoury, Thaer, Kumar, Prasanna, Papanicolau-Sengos, Antonios, Early, Amy P

Get full text

CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin by Lang, Jennifer K, Karthikeyan, Badri, Quiñones-Lombraña, Adolfo, Blair, Rachael Hageman, Early, Amy P, Levine, Ellis G, Sharma, Umesh C, Blanco, Javier G, O'Connor, Tracey

“…The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have…”
Get full text

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing by Dy, Grace K, Nesline, Mary K, Papanicolau-Sengos, Antonios, DePietro, Paul, LeVea, Charles M, Early, Amy, Chen, Hongbin, Grand'Maison, Anne, Boland, Patrick, Ernstoff, Marc S, Edge, Stephen, Akers, Stacey, Opyrchal, Mateusz, Chatta, Gurkamal, Odunsi, Kunle, Pabla, Sarabjot, Conroy, Jeffrey M, Glenn, Sean T, DeFedericis, Hanchun T, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Maochun, Wang, Yirong, Kanehira, Kazunori, Lenzo, Felicia L, Frederick, Peter, Lele, Shashikant, Galluzzi, Lorenzo, Kuvshinoff, Boris, Morrison, Carl

“…Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of…”
Get full text

320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer by Gandhi, Shipra, Forsyth, Peter, Opyrchal, Mateusz, Ahmed, Kamran, Khong, Hung, Attwood, Kristopher, Levine, Ellis, O’Connor, Tracey, Early, Amy, Fenstermaker, Robert, Prasad, Dheerendra, Takabe, Kazuaki, Czerniecki, Brian, Kalinski, Pawel

“…BackgroundBrain metastases develop in up to 50% patients with metastatic triple negative breast cancer (TNBC) and HER2+ BC and are an increasing source of…”
Get full text

Latinx Parents' Perceptions of Neighborhood Walking Safety for Their Youth With Intellectual Disabilities: A Mixed-Methods Investigation by Early, Amy, Suarez-Balcazar, Yolanda, Arias, Dalmina

“…Increased walking distance and frequency has been linked to positive health outcomes. Neighborhood walkability disproportionately impacts youth with…”
Get full text

Latinx Parents' Perceptions of Neighborhood Walking Safety for Their Youth With Intellectual Disabilities by Early, Amy, Suarez-Balcazar, Yolanda, Arias Dalmina

“…Increased walking distance and frequency has been linked to positive health outcomes. Neighborhood walkability disproportionately impacts youth with…”
Get full text

Patients' preferences for adjuvant osimertinib in non–small cell lung cancer (NSCLC) after complete surgical resection: What makes it worth it to patients? (PATT)—The Roswell Park (RP) Comprehensive Cancer Center experience by Mier-Hicks, Angel, Attwood, Kristopher, Catalfamo, Kayla, Jain, Prantesh, Chen, Hongbin, Yau, Edwin, Early, Amy P., Dy, Grace K.

“…8520 Background: There are clinical controversies surrounding the US FDA approval of Osimertinib in December 2020 as adjuvant therapy, based on disease-free…”
Get full text

Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC) by Nesline, Mary, Pabla, Sarabjot, Lee, Yong Hee, DePietro, Paul, Zhang, Shengle, Klein, Roger David, Conroy, Jeffrey M., Ramkissoon, Shakti, Early, Amy P., Deng, Lei, Dy, Grace K.

“…e21167 Background: CGIP analyzes FFPE tumor tissue by DNA/RNA sequencing for SNVs, indels, copy gain/loss, fusions, splice variants, MSI and TMB, along with…”
Get full text

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2 + breast cancer by Gandhi, Shipra, Forsyth, Peter A. J., Opyrchal, Mateusz, Ahmed, Kamran A., Attwood, Kristopher, Levine, Ellis Glenn, O'Connor, Tracey L., Early, Amy P., Fenstermaker, Robert Alan, Prasad, Dheerendra, Takabe, Kazuaki, Czerniecki, Brian J., Kalinski, Pawel

“…TPS1112 Background: Brain metastases develop in up to 50% patients (pts) with metastatic triple negative breast cancer (TNBC) and HER2 + BC, constituting an…”
Get full text

Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? by Awidi, Muhammad, Mier-Hicks, Angel, Perimbeti, Stuthi, Attwood, Kristopher, Chen, Hongbin, Jain, Prantesh, Yau, Edwin, Early, Amy, Dy, Grace K.

“…The ADAURA trial confirmed adjuvant Osimertinib's efficacy in EGFR-mutated Non–small-cell lung cancer (NSCLC), yet the limited mature overall survival (OS)…”
Get full text